Sperm analysis and serum follicle-stimulating hormone levels before and after adjuvant single-agent carboplatin therapy for clinical stage i seminoma

• Published in: Urology (Ridgewood, N.J.) Vol. 52; no. 1; pp. 117 - 119
• Main Authors: Reiter, W.J, Kratzik, C, Brodowicz, T, Haitel, A, Pokorny, A, Zielinski, C.C, Marberger, M
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.07.1998; Elsevier Science
• Subjects: Adult; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Carboplatin - therapeutic use; Chemotherapy, Adjuvant; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Follicle Stimulating Hormone - blood; Humans; Male; Medical sciences; Neoplasm Staging; Pharmacology. Drug treatments; Prospective Studies; Seminoma - blood; Seminoma - drug therapy; Seminoma - pathology; Sperm Count; Sperm Motility; Testicular Neoplasms - blood; Testicular Neoplasms - drug therapy; Testicular Neoplasms - pathology; Antineoplastic agent; Human; Orchidectomy; Spermatogenesis; Treatment efficiency; Hypothalamohypophysotesticular axis; Adjuvant treatment; Malignant tumor; Radiotherapy; Testicle; Seminoma; Chemotherapy; Treatment; Surgery; Carboplatin; Combined treatment; Biological effect; Male genital diseases; Testicular diseases
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/S0090-4295(98)00139-3

Objectives. During the past 25 years, radiotherapy has been considered the standard adjuvant treatment for clinical Stage I seminoma after orchiectomy. However, the late effects of this treatment have prompted a re-examination of the alternatives, including surveillance and adjuvant administration of carboplatin. To our knowledge, the present clinical study is the first to report the effects of two adjuvant courses of single-agent carboplatin on the pituitary–testicular axis and on sperm analysis. Methods. Twenty-two patients with clinical Stage I seminoma participated in a prospective investigation of gonadal function before and after carboplatin therapy. After orchiectomy but before chemotherapy, blood samples for determination of follicle-stimulating hormone (FSH) serum levels were obtained from all 22 patients. Seventeen patients provided a semen sample at the same time, but 5 were unable to do so. At the end of chemotherapy, all 22 patients provided repeated semen samples starting 1 year after the termination of treatment and continuing at intervals of 12 months. FSH serum levels were determined at the same time. The study period was 48 months. Results. Before chemotherapy, 2 patients (12%) had azoospermia, 9 (53%) had oligospermia, and 6 (35%) had normospermia. During the study period, sperm counts continued to increase in all patients. After 4 years, 7 patients (32%) had oligospermia and 15 (68%) normospermia. The mean prechemotherapy FSH level (15.5 IU/L) was increased in accordance with subnormal spermatogenesis, but a constant trend toward normalization was observed thereafter. Conclusions. Our results show recovery of spermatogenesis after adjuvant single-agent carboplatin for clinical Stage I seminoma in a remarkably high percentage of patients.